House members are scheduled to vote Wednesday on the Food and Drug Administration Reform Act to reauthorize the drug and user-fee programs that would expire later this year and authorize new generic and biosimilar user-fee programs.
Scheduled to expire Sept. 30, the drug and device user-fee programs allow the FDA to collect fees from the pharmaceutical and medical device industries in exchange for agreeing to meet performance goals. The House Energy and Commerce Committee
unanimously approved Rep. Fred Upton's (R-Mich.) bill (PDF)
earlier this month.
Meanwhile, the Senate last week passed
its own legislation to reauthorize drug and device user-fee programs and authorize new generic and biosimilar user-fee programs in a vote of 96 to 1.